LIVN:NASDAQLivaNova PLC Analysis

LivaNova (LIVN) is trading at $73.71, roughly 8.8% below its DCF‑derived fair value of $87.39, suggesting a modest upside. The stock sits comfortably above its 20‑day SMA (66.73) and 50‑day SMA (64.70) while the MACD histogram remains positive, signaling continued bullish momentum. Recent Q1 results delivered double‑digit revenue growth (14.3%) and earnings per share that beat expectations, prompting the company to raise its full‑year 2026 guidance and secure FDA pre‑market clearance for a key neuromodulation product. These catalysts, combined with a forward PE of 15.9 versus the industry average of 27.1, reinforce a growth‑oriented narrative.
On the fundamentals side, LIVN maintains strong gross margins (68%) and a healthy operating cash flow of $245 M, while its debt‑to‑equity ratio remains modest. Volatility is elevated at 55% over the past 30 days and beta exceeds 1.3, indicating sensitivity to market swings, yet liquidity appears solid with stable volume and a $4 B market cap. The absence of a dividend underscores the focus on reinvestment. Overall, the blend of bullish technicals, favorable earnings momentum, and an attractive valuation gap supports a positive outlook across horizons.